Market revenue in 2023 | USD 674.2 million |
Market revenue in 2030 | USD 1,624.8 million |
Growth rate | 13.4% (CAGR from 2023 to 2030) |
Largest segment | Hydrogels |
Fastest growing segment | Nanofiber Based Scaffolds |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hydrogels, Polymeric Scaffolds, Micropatterned Surface Microplates, Nanofiber Based Scaffolds |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Tecan Group AG, Becton Dickinson & Co, Medtronic PLC, Matricelf Ltd, Corning Inc, Avacta Group PLC, Vericel Corp, NuVasive, Allergan, ReproCELL, 3D Biotek, Xanofi, Molecular Matrix, Pelo Biotech, Azenta Life Sciences, Akron Biotechnology |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to scaffold technology market will help companies and investors design strategic landscapes.
Hydrogels was the largest segment with a revenue share of 41.86% in 2023. Horizon Databook has segmented the U.S. scaffold technology market based on hydrogels, polymeric scaffolds, micropatterned surface microplates, nanofiber based scaffolds covering the revenue growth of each sub-segment from 2018 to 2030.
A growing number of organ transplants and strategic developments undertaken by key companies to improve scaffold applications in organ transplants are expected to propel market growth. For instance, in April 2017, two U.S. based companies—United Therapeutics and 3D Systems—partnered up to develop solid-organ scaffolds for human transplants.
This partnership combined organ manufacturing and regenerative medicine expertise of United Therapeutics with the precision healthcare and 3D printing expertise of 3D Systems for solid-organ scaffolds, initiating with lung scaffolds.
In addition, implementation of scaffold technology in drug development and screening procedures by several pharmaceutical companies is expected to drive market growth in this country. The emergence of non-antibody protein scaffolds that can address the existing challenges faced by traditional antibody based therapies can also augment market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. scaffold technology market , including forecasts for subscribers. This country databook contains high-level insights into U.S. scaffold technology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account